APA (7th ed.) Citation

Kuo, Y., Chang, K., & Chen, H. (2022). RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan. Value in Health, 25(12), S475. https://doi.org/10.1016/j.jval.2022.09.2359

Chicago Style (17th ed.) Citation

Kuo, YC, KC Chang, and HY Chen. "RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan." Value in Health 25, no. 12 (2022): S475. https://doi.org/10.1016/j.jval.2022.09.2359.

MLA (9th ed.) Citation

Kuo, YC, et al. "RWD134 Real-World Effectiveness of Atezolizumab Plus Bevacizumab in the Patients With Hepatocellular Carcinoma: A Multi-Institutional Cohort in Taiwan." Value in Health, vol. 25, no. 12, 2022, p. S475, https://doi.org/10.1016/j.jval.2022.09.2359.